Hologic, Inc. (NASDAQ:HOLX) Shares Bought by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC raised its stake in Hologic, Inc. (NASDAQ:HOLXFree Report) by 33.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,436 shares of the medical equipment provider’s stock after acquiring an additional 4,596 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Hologic were worth $1,317,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of the stock. Orion Portfolio Solutions LLC boosted its stake in shares of Hologic by 50.3% during the third quarter. Orion Portfolio Solutions LLC now owns 74,422 shares of the medical equipment provider’s stock worth $5,165,000 after buying an additional 24,907 shares during the period. New Mexico Educational Retirement Board boosted its stake in shares of Hologic by 7.5% during the third quarter. New Mexico Educational Retirement Board now owns 12,850 shares of the medical equipment provider’s stock worth $892,000 after buying an additional 900 shares during the period. Daiwa Securities Group Inc. boosted its stake in shares of Hologic by 59.2% during the third quarter. Daiwa Securities Group Inc. now owns 40,213 shares of the medical equipment provider’s stock worth $2,791,000 after buying an additional 14,949 shares during the period. Empirical Finance LLC boosted its stake in shares of Hologic by 9.8% during the third quarter. Empirical Finance LLC now owns 8,767 shares of the medical equipment provider’s stock worth $608,000 after buying an additional 786 shares during the period. Finally, Venturi Wealth Management LLC acquired a new stake in shares of Hologic during the third quarter worth about $29,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Stock Performance

Shares of HOLX opened at $75.02 on Friday. Hologic, Inc. has a 12-month low of $64.02 and a 12-month high of $82.45. The stock has a market cap of $17.51 billion, a P/E ratio of 38.28, a PEG ratio of 2.50 and a beta of 1.01. The company has a current ratio of 3.97, a quick ratio of 3.29 and a debt-to-equity ratio of 0.52. The company has a 50-day moving average of $76.25 and a two-hundred day moving average of $73.66.

Hologic (NASDAQ:HOLXGet Free Report) last issued its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $0.98 by $0.05. Hologic had a net margin of 11.78% and a return on equity of 18.91%. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion. During the same period last year, the company posted $1.06 EPS. The company’s revenue was down .8% on a year-over-year basis. As a group, research analysts predict that Hologic, Inc. will post 4.08 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on HOLX shares. Evercore ISI increased their target price on shares of Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research note on Thursday, April 4th. Citigroup raised Hologic from a “neutral” rating to a “buy” rating and increased their target price for the stock from $80.00 to $95.00 in a research note on Wednesday, April 3rd. UBS Group lifted their price target on Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a research note on Friday, February 2nd. Argus increased their price objective on Hologic from $89.00 to $95.00 and gave the stock a “buy” rating in a research report on Thursday, May 9th. Finally, StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. Five analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $85.60.

Check Out Our Latest Research Report on Hologic

Insider Activity

In other news, Director Charles J. Dockendorff sold 1,465 shares of Hologic stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $76.21, for a total transaction of $111,647.65. Following the completion of the sale, the director now directly owns 1,572 shares in the company, valued at $119,802.12. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, Director Charles J. Dockendorff sold 1,465 shares of the company’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $76.21, for a total transaction of $111,647.65. Following the transaction, the director now owns 1,572 shares of the company’s stock, valued at $119,802.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Scott T. Garrett sold 16,441 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the transaction, the director now directly owns 48,611 shares in the company, valued at approximately $3,670,130.50. The disclosure for this sale can be found here. Company insiders own 1.75% of the company’s stock.

Hologic Profile

(Free Report)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Featured Stories

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLXFree Report).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.